Neurocrine Bioscienc (NBIX) 48.46 $NBIX Neurocrine

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neurocrine Bioscienc (NBIX) 48.46 $NBIX

Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA(TM) for VMAT2 Inhibitor Valbenazine
PR Newswire - Wed Aug 31, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name "INGREZZA(TM)" for the Company's once-daily vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine. The Company has recently announced the submission of a New Drug Application (NDA) with the FDA for valbenazine in tardive dyskinesia and is also exploring its utility in Tourette syndrome.
NBIX: 48.46 (-0.71)

Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia
PR Newswire - Mon Aug 29, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily dosing of valbenazine in treating tardive dyskinesia.
NBIX: 48.46 (-0.71)

SmarTrend Watching for Potential Pullback in Shares of Neurocrine Biosciences After 3.31% Gain
Comtex SmarTrend(R) - Mon Aug 22, 3:48PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $48.75 to a high of $50.28. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $48.61 on volume of 331,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 48.46 (-0.71)

Neurocrine Biosciences Reports Second Quarter 2016 Results
PR Newswire - Wed Aug 03, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2016. For the second quarter of 2016, the Company reported a net loss of $40.3 million, or $0.46 loss per share, compared to a net loss of $24.0 million, or $0.28 loss per share, for the same period in 2015. For the six months ended June 30, 2016, the Company reported a net loss of $59.5 million, or $0.69 loss per share, as compared to a net loss of $25.2 million, or $0.30 loss per share, for the first half of last year.
NBIX: 48.46 (-0.71)

Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
PR Newswire - Thu Jul 28, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in children, adolescents and adults with Tourette syndrome.
NBIX: 48.46 (-0.71)

Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results
PR Newswire - Wed Jul 27, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2016 results after the Nasdaq market closes on Wednesday, August 3, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, August 3, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 48.46 (-0.71)

Notable Thursday Option Activity: NBIX, RAD, SEAS
DividendChannel.com - Thu Jun 23, 2:29PM CDT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Neurocrine Biosciences, Inc. , where a total of 4,984 contracts have traded so far, representing approximately 498,400 underlying shares.
NBIX: 48.46 (-0.71)

Watch for Neurocrine Biosciences to Potentially Rebound After Falling 4.83% Yesterday
Comtex SmarTrend(R) - Tue Jun 21, 3:42PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $41.70 to a high of $44.86. Yesterday, the shares fell 4.8%, which took the trading range below the 3-day low of $44.04 on volume of 786,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 48.46 (-0.71)

Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 2:45PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 Healthcare Conference in New York City.
NBIX: 48.46 (-0.71)

nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 48.46 (-0.71), TRGT: 0.96 (-1.25), CBIO: 1.20 (-0.06), PTN: 0.51 (+0.01), IDXX: 112.68 (-0.38), BIOD: 0.43 (-0.01)

Neurocrine Biosciences Rises 8.70% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 2:08PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $48.49 to a high of $50.87. Yesterday, the shares gained 8.7%, which took the trading range above the 3-day high of $49.44 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 48.46 (-0.71)

Neurocrine Biosciences Falls 3.33% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu May 26, 2:35PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $44.41 to a high of $46.47. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $46.01 on volume of 513,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 48.46 (-0.71)

Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors
PR Newswire - Fri May 20, 8:00AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective just prior to the 2016 Annual Meeting of Shareholders. Mr. Mitchell has been a member of the Board of Directors for over thirteen years serving in various capacities on the audit, compensation, and nominating and corporate governance committees.
NBIX: 48.46 (-0.71)

After Yesterday's Rally of 4.19% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 16, 4:19PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $43.79 to a high of $46.11. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $44.60 on volume of 434,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 48.46 (-0.71)

Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Fri May 06, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas.
NBIX: 48.46 (-0.71)

Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta
PR Newswire - Fri May 06, 7:30AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will include an evaluation of the impact of valbenazine on the psychiatric stability of subjects with underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder), data assessing the effect of valbenazine stratified by baseline tardive dyskinesia severity, and an evaluation of valbenazine with concomitant antipsychotic use. The APA Annual Meeting is the largest international conference of psychiatrists and behavioral health specialists, bringing together an estimated 13,000 clinicians and scientists to address current topics in psychiatry.
NBIX: 48.46 (-0.71)

Neurocrine reports 1Q loss
Automated Insights - Thu May 05, 5:22PM CDT
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Thursday reported a loss of $19.3 million in its first quarter.
NBIX: 48.46 (-0.71)

Neurocrine Biosciences Reports First Quarter 2016 Results
PR Newswire - Thu May 05, 3:01PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2016. For the first quarter of 2016, the Company reported a net loss of $19.3 million, or $0.22 loss per share, compared to a net loss of $1.2 million, or $0.01 loss per share, for the same period in 2015.
NBIX: 48.46 (-0.71)

Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results
PR Newswire - Fri Apr 29, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2016 results after the Nasdaq market closes on Thursday, May 5, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, May 5, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 48.46 (-0.71)

Neurocrine Biosciences to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Wed Apr 27, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Deutsche Bank 41st Annual Health Care Conference in Boston.
NBIX: 48.46 (-0.71), DB: 14.75 (+0.36)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 86

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 81

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 61

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 103

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 33

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 115

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 86

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 113

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 76

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading

Top 5 Most Recently Viewed Articles

SerpApi Reduces AI Token Use with Markdown Output

Updated Category News Views 80

A Big Leap for AI in Data Efficiency Well, here we are watching yet another tech company changing the game—or trying to, at least. SerpApi is shaking things up by announcing a new Markdown output feature, geared specifically toward AI developers. This is some impressive magic where structured search data gets spoon-fed to large language models (LLMs) in a format that's...

Continue Reading
Callinex Mines Reports Promising Exploration at Pine Bay

Updated Category News Views 195

Exploring New Horizons: Callinex Mines' Latest Discoveries Callinex Mines Inc. (TSXV: CNX) recently shared exciting updates from its exploration activities at the Pine Bay Camp, located in the Flin Flon Mining District. The drilling program has uncovered significant mineralization, particularly at the new Blueberry target area. Key Highlights from the Recent Drilling...

Continue Reading
Investor Concerns Grow Over Construction Partners, Inc. Shares

Updated Category News Views 136

Investor Concerns Grow Over Construction Partners, Inc. Shares Pomerantz LLP is currently examining claims on behalf of investors of Construction Partners, Inc. (NYSE: ROAD). This investigation aims to clarify whether the company’s management may have engaged in unlawful business practices or misrepresentation of its financial state. Understanding the Allegations Recent...

Continue Reading
Salesforce Earnings: Navigating Current Market Challenges

Updated Category News Views 75

Salesforce Stock Insights Amid Market Challenges Salesforce (NYSE: CRM) is facing notable resistance in its stock price, indicating potential difficulties in achieving new highs soon. While the recent Q2 results were encouraging, showcasing improved guidance, the market continues to grapple with various challenges. Issues such as slowing growth, macroeconomic pressures,...

Continue Reading
Investors Concerned About Synopsys, Inc. and Possible Losses

Updated Category News Views 147

Investigation into Synopsys, Inc. (SNPS) In recent times, Synopsys, Inc. has been under scrutiny for potential violations of federal securities laws. This investigation is particularly significant for the investors of Synopsys, Inc., commonly referred to as Synopsys. Understanding What Happened On September 9, 2025, Synopsys unveiled its financial results for the third...

Continue Reading